Alimera Sciences Receives $20 Million From Ocumension Therapeutics
April 14, 2021 09:00 ET
|
Alimera Sciences, Inc.
Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone paymentsOcumension makes a $10 million equity investment in...
Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021
April 09, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference
March 18, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland
March 17, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, March 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference
March 11, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, March 11, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Reports Fourth Quarter and 2020 Results
February 24, 2021 16:05 ET
|
Alimera Sciences, Inc.
Fourth Quarter Highlights: Consolidated Net Revenue of $13.8 Million Up 10% vs. Third Quarter of 2020 Consolidated Net Revenue Down 20% vs. Fourth Quarter of 2019 Due to COVID-19...
Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications
February 18, 2021 08:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update
February 17, 2021 08:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference
February 15, 2021 08:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the...